Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADVERUM BIOTECHNOLOGIES, INC.

(ADVM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
2.27(c) 2.17(c) 2.17(c) 2.23(c) 2.31(c) Last
3 083 184 1 538 000 1 703 255 2 273 666 11 880 223 Volume
+1.34% -4.41% 0.00% +2.76% +3.59% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 6,25 M - -
Net income 2021 -143 M - -
Net cash position 2021 282 M - -
P/E ratio 2021 -1,58x
Yield 2021 -
Sales 2022 1,25 M - -
Net income 2022 -151 M - -
Net cash position 2022 247 M - -
P/E ratio 2022 -1,83x
Yield 2022 -
Capitalization 227 M 227 M -
EV / Sales 2021 -8,82x
EV / Sales 2022 -16,0x
Nbr of Employees 167
Free-Float 97,9%
More Financials
Company
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and... 
More about the company
Ratings of Adverum Biotechnologies, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about ADVERUM BIOTECHNOLOGIES, INC.
09/09ADVERUM BIOTECHNOLOGIES, INC. : Change in Directors or Principal Officers (form ..
AQ
09/09Adverum Biotechnologies, Inc. Announces Executive Changes
CI
08/23Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice Pre..
GL
08/23Adverum Biotechnologies, Inc Appoints Jim Wang as Senior Vice President, Head..
CI
08/11ADVERUM BIOTECHNOLOGIES, INC. : Change in Directors or Principal Officers (form ..
AQ
08/11Adverum Biotechnologies, Inc. Announces Resignation of Christopher Derespino ..
CI
08/05ADVERUM BIOTECHNOLOGIES : Q2 Earnings Snapshot
AQ
08/05ADVERUM BIOTECHNOLOGIES : Management's Discussion and Analysis of Financial Cond..
AQ
08/05Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter..
CI
08/05ADVERUM BIOTECHNOLOGIES, INC. : Results of Operations and Financial Condition, F..
AQ
08/05ADVERUM BIOTECHNOLOGIES : Reports Second Quarter 2021 Results
AQ
07/23ADVERUM BIOTECHNOLOGIES : Goldman Sachs Downgrades Adverum Biotechnologies to Ne..
MT
07/23ADVERUM BIOTECHNOLOGIES : Chardan Adjusts Price Target on Adverum Biotechnologie..
MT
07/23ADVERUM BIOTECHNOLOGIES : SVB Leerink Adjusts Adverum Biotechnologies' Price Tar..
MT
07/23ADVERUM BIOTECHNOLOGIES : Cantor Fitzgerald Downgrades Adverum Biotechnologies t..
MT
More news
News in other languages on ADVERUM BIOTECHNOLOGIES, INC.

- No features available -

More news
Analyst Recommendations on ADVERUM BIOTECHNOLOGIES, INC.
More recommendations
Chart ADVERUM BIOTECHNOLOGIES, INC.
Duration : Period :
Adverum Biotechnologies, Inc. Technical Analysis Chart | ADVM | US00773U1088 | MarketScreener
Technical analysis trends ADVERUM BIOTECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 2,31 $
Average target price 3,57 $
Spread / Average Target 54,6%
EPS Revisions
Managers and Directors
Laurent Fischer President, Chief Executive Officer & Director
Jack Anthony Thrift Chief Financial & Accounting Officer
Clarence Patrick Machado Chairman
Angela Thedinga Chief Technology Officer
Julie Clark Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ADVERUM BIOTECHNOLOGIES, INC.-78.69%227
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850